The in vitro studies corroborated that expression of PDGFRα remarkably increased when β-catenin was inhibited, indicating that PDGFRα and β-catenin might account for two divergent carcinogenic mechanisms and distinct subgroups of HCC patients [13]. This evidence concerns the gene PDGFRA and hepatocellular carcinoma.